{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:42:04Z","timestamp":1790080924716,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T00:00:00Z","timestamp":1438732800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s40262-015-0304-0","type":"journal-article","created":{"date-parts":[[2015,8,4]],"date-time":"2015-08-04T12:45:02Z","timestamp":1438692302000},"page":"33-45","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib"],"prefix":"10.1007","volume":"55","author":[{"given":"Srinivasan","family":"Ramanathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shringi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,5]]},"reference":[{"issue":"4","key":"304_CR1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0960-9822(06)00122-9","volume":"7","author":"DR Alessi","year":"1997","unstructured":"Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 1997;7(4):261\u20139.","journal-title":"Curr Biol"},{"issue":"12","key":"304_CR2","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/nrc1753","volume":"5","author":"AG Bader","year":"2005","unstructured":"Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer. 2005;5(12):921\u20139.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"304_CR3","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1084\/jem.20020805","volume":"196","author":"E Clayton","year":"2002","unstructured":"Clayton E, Bardi G, Bell SE, Chantry D, Downes CP, Gray A, et al. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B\u00a0cell development and activation. J Exp Med. 2002;196(6):753\u201363.","journal-title":"J Exp Med"},{"issue":"4","key":"304_CR4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri1056","volume":"3","author":"K Okkenhaug","year":"2003","unstructured":"Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol. 2003;3(4):317\u201330.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"304_CR5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.tibs.2005.02.008","volume":"30","author":"B Vanhaesebroeck","year":"2005","unstructured":"Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci. 2005;30(4):194\u2013204.","journal-title":"Trends Biochem Sci"},{"issue":"5","key":"304_CR6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","volume":"11","author":"B Vanhaesebroeck","year":"2010","unstructured":"Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11(5):329\u201341.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"304_CR7","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood.V98.10.3050","volume":"98","author":"A Bernal","year":"2001","unstructured":"Bernal A, Pastore RD, Asgary Z, Keller SA, Cesarman E, Liou HC, et al. Survival of leukemic B\u00a0cells promoted by engagement of the antigen receptor. Blood. 2001;98(10):3050\u20137.","journal-title":"Blood"},{"issue":"5300","key":"304_CR8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1126\/science.275.5300.661","volume":"275","author":"H Dudek","year":"1997","unstructured":"Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science. 1997;275(5300):661\u20135.","journal-title":"Science"},{"issue":"2","key":"304_CR9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","volume":"30","author":"JA Fresno Vara","year":"2004","unstructured":"Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K\/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30(2):193\u2013204.","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"304_CR10","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/ijc.22862","volume":"121","author":"S Shukla","year":"2007","unstructured":"Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, Gupta S. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer. 2007;121(7):1424\u201332.","journal-title":"Int J Cancer"},{"issue":"16","key":"304_CR11","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1182\/blood-2010-11-315705","volume":"117","author":"SE Herman","year":"2011","unstructured":"Herman SE, Lapalombella R, Gordon AL, Ramanunni A, Blum KA, Jones J, et al. The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood. 2011;117(16):4323\u20137.","journal-title":"Blood"},{"issue":"13","key":"304_CR12","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","volume":"118","author":"J Hoellenriegel","year":"2011","unstructured":"Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, et al. The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118(13):3603\u201312.","journal-title":"Blood"},{"issue":"2","key":"304_CR13","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","volume":"117","author":"BJ Lannutti","year":"2011","unstructured":"Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117(2):591\u20134.","journal-title":"Blood"},{"issue":"11","key":"304_CR14","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008\u201318.","journal-title":"N Engl J Med"},{"issue":"11","key":"304_CR15","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997\u20131007.","journal-title":"N Engl J Med"},{"issue":"21","key":"304_CR16","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1182\/blood.V124.21.330.330","volume":"124","author":"JP Sharman","year":"2014","unstructured":"Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, et al. Second interim analysis of phase\u00a03 study of idelalisib plus rituximab for relapsed CLL: efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors. Blood. 2014;124(21):330.","journal-title":"Blood"},{"issue":"21","key":"304_CR17","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V124.21.3343.3343","volume":"124","author":"JC Barrientos","year":"2014","unstructured":"Barrientos JC, Coutre SE, Vos S, Wagner-Johnston ND, Flinn IW, Sharman JP, et al. Long-term follow-up of a phase\u00a01 trial of idelalisib (Zydelig\u00ae) in combination with bendamustine (B), bendamustine\/rituximab (BR), fludarabine (F), chlorambucil (Chl), or chlorambucil\/rituximab (ChlR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood. 2014;124(21):3343.","journal-title":"Blood"},{"issue":"13","key":"304_CR18","doi-asserted-by":"crossref","first-page":"8439","DOI":"10.1074\/jbc.M114.634683","volume":"290","author":"JR Somoza","year":"2015","unstructured":"Somoza JR, Koditek D, Villasenor AG, Novikov N, Wong MH, Liclican A, et al. Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase delta. J Biol Chem. 2015;290(13):8439\u201346.","journal-title":"J Biol Chem"},{"issue":"15","key":"304_CR19","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1158\/1078-0432.CCR-11-1402","volume":"18","author":"SE Herman","year":"2012","unstructured":"Herman SE, Johnson AJ. Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia. Clin Cancer Res. 2012;18(15):4013\u20138.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"304_CR20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/ejh.12427","volume":"94","author":"V Seda","year":"2015","unstructured":"Seda V, Mraz M. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol. 2015;94(3):193\u2013205.","journal-title":"Eur J Haematol"},{"issue":"3","key":"304_CR21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ccr.2014.02.012","volume":"25","author":"B Vanhaesebroeck","year":"2014","unstructured":"Vanhaesebroeck B, Khwaja A. PI3Kdelta inhibition hits a sensitive spot in B cell malignancies. Cancer Cell. 2014;25(3):269\u201371.","journal-title":"Cancer Cell"},{"issue":"1","key":"304_CR22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1517\/21678707.2014.978858","volume":"3","author":"Q Yang","year":"2015","unstructured":"Yang Q, Modi P, Ramanathan S, Qu\u00e9va C, Gandhi V. Idelalisib for the treatment of B-cell malignancies. Expert Opinion Orphan Drugs. 2015;3(1):109\u201323.","journal-title":"Expert Opinion Orphan Drugs."},{"issue":"22","key":"304_CR23","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","volume":"123","author":"JR Brown","year":"2014","unstructured":"Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed\/refractory chronic lymphocytic leukemia. Blood. 2014;123(22):3390\u20137.","journal-title":"Blood"},{"key":"304_CR24","doi-asserted-by":"crossref","unstructured":"Webb HK, Chen H, Yu AS, Peterman S, Holes L, Lannutti B, et al. Clinical pharmacokinetics of CAL-101, a p110\u03b4 isoform-selective PI3K inhibitor, following single- and multiple-dose administration in healthy volunteers and patients with hematological malignancies. ASH Annual Meeting Abstracts. 2010;116(21):1774.","DOI":"10.1182\/blood.V116.21.1774.1774"},{"issue":"21","key":"304_CR25","doi-asserted-by":"crossref","first-page":"5054","DOI":"10.1182\/blood.V122.21.5054.5054","volume":"122","author":"F Jin","year":"2013","unstructured":"Jin F, Zhou H, Fang L, Li X, Newcomb T, Dansey R, et al. Exposure\u2013response of idelalisib, a novel PI3K\u03b4 inhibitor, in the treatment of hematologic malignancies. Blood. 2013;122(21):5054.","journal-title":"Blood"},{"key":"304_CR26","first-page":"S69","volume":"41","author":"F Jin","year":"2014","unstructured":"Jin F, Gao Y, Zhou H. Population pharmacokinetic modeling of idelalisib, a novel PI3K\u03b4 inhibitor, in healthy subjects and patients with hematologic malignancies. J Pharmacokinet Pharmacodyn. 2014;41:S69.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"21","key":"304_CR27","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1182\/blood.V122.21.5570.5570","volume":"122","author":"F Jin","year":"2013","unstructured":"Jin F, Robeson M, Zhou H, Kwan E, Ramanathan S. Pharmacokinetics, metabolism and excretion of idelalisib. Blood. 2013;122(21):5570.","journal-title":"Blood"},{"key":"304_CR28","first-page":"850","volume":"26","author":"H Chen","year":"2012","unstructured":"Chen H, Evarts J, Webb H, Ulrich R. Biotransformation of GS-1101 (CAL-101), a potent and selective inhibitor of PI3K delta for the treatment of patients with hematologic malignancies. FASEB J. 2012;26:850.","journal-title":"FASEB J."},{"key":"304_CR29","first-page":"S84","volume":"97","author":"F Jin","year":"2015","unstructured":"Jin F, Zhou H, Gao Y, Li X, Newcomb T, Ramanathan S. Effect of intrinsic and extrinsic factors on pharmacokinetics of idelalisib, a novel PI3K\u03b4 inhibitor, in patients with hematologic malignancies. Clin Pharmacol Ther. 2015;97(Suppl\u00a01):S84.","journal-title":"Clin Pharmacol Ther"},{"key":"304_CR30","author":"F Jin","year":"2015","unstructured":"Jin F, Robeson M, Zhou H, Hisoire G, Ramanathan S. The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment. J Clin Pharmacol. 2015. doi: 10.1002\/jcph.504 (Epub 2015 Mar 27).","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"304_CR31","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1517\/17425255.2012.663352","volume":"8","author":"E Garattini","year":"2012","unstructured":"Garattini E, Terao M. The role of aldehyde oxidase in drug metabolism. Expert Opin Drug Metab Toxicol. 2012;8(4):487\u2013503.","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"5","key":"304_CR32","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2133\/dmpk.21.357","volume":"21","author":"M Nishimura","year":"2006","unstructured":"Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human phase\u00a0I metabolizing enzymes except for cytochrome P450 and phase\u00a0II metabolizing enzymes. Drug Metab Pharmacokinet. 2006;21(5):357\u201374.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"21","key":"304_CR33","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1182\/blood.V122.21.5572.5572","volume":"122","author":"F Jin","year":"2013","unstructured":"Jin F, Robeson M, Zhou H, Hisoire G, Ramanathan S. The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment. Blood. 2013;122(21):5572.","journal-title":"Blood"},{"key":"304_CR34","author":"F Jin","year":"2015","unstructured":"Jin F, Robeson M, Zhou H, Moyer C, Wilbert S, Murray B, et al. Clinical drug interaction profile of idelalisib in healthy subjects. J Clin Pharmacol. 2015. doi: 10.1002\/jcph.495 (Epub 2015 Mar 11).","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"304_CR35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/clpt.2008.195","volume":"85","author":"KS Fenner","year":"2009","unstructured":"Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, et al. Drug\u2013drug interactions mediated through P-glycoprotein: clinical relevance and in\u00a0vitro\u2013in\u00a0vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther. 2009;85(2):173\u201381.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"304_CR36","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1124\/dmd.107.016089","volume":"35","author":"V Dixit","year":"2007","unstructured":"Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos. 2007;35(10):1853\u20139.","journal-title":"Drug Metab Dispos"},{"key":"304_CR37","first-page":"S83","volume":"97","author":"F Jin","year":"2015","unstructured":"Jin F, Sharma S, Zhou H, Gao Y, Li X, Newcomb T, et al. Effect of acid reducing agents on the pharmacokinetics of idelalisib, a novel PI3K\u03b4 inhibitor, in patients with hematologic malignancies. Clin Pharmacol Ther. 2015;97(Suppl\u00a01):S83.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-015-0304-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-015-0304-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-015-0304-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T21:20:46Z","timestamp":1599427246000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-015-0304-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,5]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["304"],"URL":"https:\/\/doi.org\/10.1007\/s40262-015-0304-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,5]]}}}